Reduzierte Dosis von TKI führt nicht zu Wirkungsverlust bei Patienten mit aktivierender EGFR-Mutation

  • N. Reinmuth, D. Heigener, T. Goldmann, I. Watermann, M. Reck
  • Pneumologie, September 2014, Thieme Publishing Group
  • DOI: 10.1055/s-0034-1377927

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1055/s-0034-1377927

The following have contributed to this page: Professor Torsten Goldmann